Program
biafungin acetate
Also written as “Rezafungin Acetate” and “Rezafungin Acetate / Co Trimoxazole”.
Its studies are mostly in Pulmonary Aspergillosis · Invasive Fungal Infections · Pneumonia, Pneumocystis, led by Mundipharma.
Furthest: phase 2, since Apr 4, 20233 company-led studies, 2 open or runningNext primary completion: Nov 30, 2026 (phase 2)
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Mundipharma | 32 open or running | phase 2since Apr 4, 2023 | Sep 1, 2022 | Nov 30, 2026phase 2 · NCT06794554 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Sep 1, 2022First study: phase 1 study in Invasive Fungal InfectionsFirst studyNCT05534529 · 32 enrolled · Germany, Spain, United Kingdom
- Apr 4, 2023Phase 2 study in Pneumonia, PneumocystisNCT05835479 · 50 planned · South Africa
- Nov 26, 2024Phase 2 study in Chronic Pulmonary AspergillosisNCT06794554 · 60 enrolled · Austria, Belgium, France and more
Ahead
- Nov 30, 2026Primary completion: phase 2 study in Chronic Pulmonary AspergillosisNCT06794554
TargetBeta
A vaccine: it acts on a pathogen, not a human gene.
“Candida inhibitor”ChEMBL 37, by rule
Studies
All 3 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT06794554Chronic Pulmonary Aspergillosis · Austria, Belgium, France and more | 2 | Active, not recruiting | Nov 30, 2026 | 60 |
| NCT05835479Pneumonia, Pneumocystis · South Africa | 2 | Recruiting | May 2025 | 50 |
| NCT05534529Invasive Fungal Infections · Germany, Spain, United Kingdom | 1 | Terminated | May 23, 2024 | 32 |
How it is read
Names in the registry
- “Rezafungin Acetate”, 2 entries
- “Rezafungin Acetate / Co Trimoxazole”, 1 entry
Conditions, from the studies’ own filings
- Pulmonary Aspergillosis, 1 study
- Invasive Fungal Infections, 1 study
- Pneumonia, Pneumocystis, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.